.

Subscribe for Complete Access

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Cerilliant
Harvard Business School
McKinsey
Boehringer Ingelheim
Fish and Richardson
Moodys
Dow
Medtronic
Deloitte

Generated: July 28, 2017

DrugPatentWatch Database Preview

Darifenacin hydrobromide - Generic Drug Details

« Back to Dashboard

What are the generic sources for darifenacin hydrobromide and what is the scope of darifenacin hydrobromide patent protection?

Darifenacin hydrobromide
is the generic ingredient in two branded drugs marketed by Torrent Pharms Ltd, Apil, Aurobindo Pharma Ltd, Jubilant Generics, Cipla Ltd, and Anchen Pharms, and is included in six NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Darifenacin hydrobromide has forty-five patent family members in thirty-one countries.

There are nineteen drug master file entries for darifenacin hydrobromide. Ten suppliers are listed for this compound.

Summary for Generic Name: darifenacin hydrobromide

Tradenames:2
Patents:1
Applicants:6
NDAs:6
Drug Master File Entries: see list19
Suppliers / Packagers: see list10
Bulk Api Vendors: see list41
Clinical Trials: see list76
Patent Applications: see list26
Therapeutic Class:Genitourinary Agents
Drug Prices:see low prices
DailyMed Link:darifenacin hydrobromide at DailyMed

Pharmacology for Ingredient: darifenacin hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513-002Dec 22, 2004ABRXYesYes► Subscribe► SubscribeY ► Subscribe
Anchen Pharms
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL091190-001Mar 13, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Aurobindo Pharma Ltd
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL206743-002Sep 19, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Torrent Pharms Ltd
DARIFENACIN HYDROBROMIDE
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL205209-001Nov 17, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Apil
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513-001Dec 22, 2004ABRXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: darifenacin hydrobromide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Apil
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513-001Dec 22, 2004► Subscribe► Subscribe
Apil
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513-002Dec 22, 2004► Subscribe► Subscribe
Apil
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513-002Dec 22, 2004► Subscribe► Subscribe
Apil
ENABLEX
darifenacin hydrobromide
TABLET, EXTENDED RELEASE;ORAL021513-001Dec 22, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: darifenacin hydrobromide

Country Document Number Estimated Expiration
Germany69632753► Subscribe
Taiwan442300► Subscribe
Spain2224002► Subscribe
South Africa9607745► Subscribe
European Patent Office1245231► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DARIFENACIN HYDROBROMIDE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C012/2005Ireland► SubscribeSPC012/2005, 20060725, EXPIRES: 20191021
/2005Austria► SubscribePRODUCT NAME: DARIFENACIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ HIEVON; REGISTRATION NO/DATE: EU/1/04/294/001- EU/1/04/294/012 20041022
2005 00020Denmark► Subscribe
0190Netherlands► Subscribe300190, 20160821, EXPIRES: 20191021
00191Netherlands► SubscribePRODUCT NAME: DARIFENACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET HYDROBROMIDE; REGISTRATION NO/DATE: EU1/04/294/001 - 012, 20041022
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Baxter
Boehringer Ingelheim
Fuji
Farmers Insurance
Argus Health
Merck
Covington
QuintilesIMS
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot